Alaunos Therapeutics Inc. has announced the appointment of Michael A. Jerman as a new director, effective immediately. Jerman fills the vacancy left by Dale Curtis Hogue's resignation and will also serve as the chair of the Audit Committee and a member of the Compensation Committee, replacing Holger Weis, who has recently been appointed Chief Executive Officer of the company.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.